Jeffrey W. Albers

Biography

Mr. Jeffrey W. Albers, also known as Jeff, J.D., MBA has been the Chief Executive Officer and President of Blueprint Medicines Corp since July 2014. Mr. Albers has been President of Algeta US at Algeta ASA since January 15, 2012. He works closely with Algeta's senior management as part of the executive management team to enable Algeta's US commercial operations; the plans for which include the phased building of a sales force and a marketing and medical affairs team ahead of the launch of Alpharadin (radium-223 chloride) for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases, pending approval. Prior to Algeta, he served at Genzyme (Sanofi), where he spent seven years in senior commercial and corporate development positions and also served as its Vice President of US Hematology & Oncology Business. In this role, Mr. Albers was P&L responsible for a USD 250 m business that included multiple marketed products along with a pipeline of products to treat hematologic and solid tumor malignancies. He built and led a 135-person team spanning sales, operations, marketing, managed care, pricing and reimbursement, training and medical affairs. He was also involved in evaluating in-licensing opportunities. Mr. Albers played a key role in the successful US launch of Mozobil and integrating Campath and Leukine into the portfolio involving a significant field force restructuring. Prior to Genzyme, he spent five years, from 2000 to 2005 as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo, where he focused on life sciences transactional work. He has prior experience as a sales representative for Pfizer, Inc. He has been a Director of Blueprint Medicines Corp since July 2014 and Magenta Therapeutics, Inc. since October 24, 2017. He holds a B.Sc. in Marketing from Indiana University and a law degree (J.D.) and MBA degree from Georgetown University (Washington, DC).

Research Interest

Hematology & Oncology Business